136 Chapter 4 19. Patel, M.R., et al., Cardiovascular Events in Patients With Fabry Disease: Natural History Data From the Fabry Registry. Journal of the American College of Cardiology, 2011. 57(9): p. 1093-1099. 20. Hopkin, R.J., et al., Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry. Mol Genet Metab, 2016. 119(1-2): p. 151-9. 21. Zada, M., et al., Basal Segmental Longitudinal Strain: A Marker of Subclinical Myocardial Involvement in Anderson-Fabry Disease. J Am Soc Echocardiogr, 2021. 34(4): p. 405-413. e2. 22. Talbot, A.S., N.T. Lewis, and K.M. Nicholls, Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease. Heart, 2015. 101(4): p. 287-293. 23. Rob, D., et al., Heart failure in Fabry disease revisited: application of current heart failure guidelines and recommendations. ESC Heart Fail, 2022. 24. van Grootel, R.W.J., et al., Echocardiographic chamber quantification in a healthy Dutch population. Neth Heart J, 2017. 25(12): p. 682-690. 26. Lang, R.M., et al., Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging, 2015. 16(3): p. 233-70. 27. Nagueh, S.F., et al., Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr, 2016. 29(4): p. 277-314. 28. Levey, A.S., et al., A new equation to estimate glomerular filtration rate. Ann Intern Med, 2009. 150(9): p. 604-12. 29. Schielzeth, H., et al., Robustness of linear mixed-effects models to violations of distributional assumptions. Methods in Ecology and Evolution, 2020. 11(9): p. 1141-1152. 30. Vedder, A.C., et al., Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS One, 2007. 2(7): p. e598. 31. Biegstraaten, M., et al., Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis, 2015. 10: p. 36. 32. El Sayed, M., et al., ECG Changes during Adult Life in Fabry Disease: Results from a Large Longitudinal Cohort Study. Diagnostics, 2023. 13(3): p. 354. 33. Umer, M., et al., Cardiac involvement in Fabry Disease and the Role of Multimodality Imaging in Diagnosis and Disease Monitoring. Current Problems in Cardiology, 2022: p.24 101439. 34. Weidemann, F., et al., Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation, 2009. 119(4): p. 524-9.
RkJQdWJsaXNoZXIy MTk4NDMw